Effect of intermittent administration of sustained release isosorbide dinitrate (sr-ISDN) in rats with pressure-overload heart

Journal of Veterinary Medical Science

Volumn 68, Issue 3, 2006, Pages 213-217

  Shimamura, Shunsuke ^a   Endo, Hayato ^a   Kutsuna, Hiromi ^a   Kobayashi, Masayuki ^a   Hirao, Hidehiro ^a   Shimizu, Miki ^a   Tanaka, Ryou ^a   Yamane, Yoshihisa ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

Aortic constrict model; Cardiac fibrosis; Cardiac hypertrophy; Isosorbide dinitrate; Rat

Indexed keywords

ISOSORBIDE DINITRATE; NITRIC OXIDE DONOR;

ABDOMINAL AORTA; ANIMAL; ARTICLE; BODY WEIGHT; CYTOCHEMISTRY; CYTOLOGY; DELAYED RELEASE FORMULATION; DISEASE MODEL; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; MALE; ORAL DRUG ADMINISTRATION; ORGAN SIZE; PATHOLOGY; RAT; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; AORTA, ABDOMINAL; BODY WEIGHT; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; ENDOMYOCARDIAL FIBROSIS; HISTOCYTOCHEMISTRY; HYPERTROPHY, LEFT VENTRICULAR; ISOSORBIDE DINITRATE; MALE; MYOCYTES, CARDIAC; NITRIC OXIDE DONORS; ORGAN SIZE; RATS; RATS, WISTAR;

ANIMALIA; RATTUS NORVEGICUS;

EID: 33645678627     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.68.213     Document Type: Article

References (34)

1. Aronow, S. 1980. Sustained hemodynamic and antianginal effects of high dose oral isosorbide dinitrate. Nouv. Presse. Med. 9:2483-2486.
2. Bledsoe, G., Chao, L. and Chao, J. 2003. Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 285: H1479-H1488.
3. Bomber, J.W. and De Tullio, P.L. 1995. Oral nitrate preparations: an update. Am. Fam. Physician. 52: 2331-2337.
4. Cheitlin, M.D., Robinowitz, M., McAllister, H., Hoffman, J.I., Bharati, S. and Lev, M. 1980. The distribution of fibrosis in the left ventricle in congenital aortic stenosis and coarctation of the aorta. Circulation 62: 823-830.
5. Cohn, J.N., Archibald, D.G., Ziesche, S., Franciosa, J.A., Harston, W.E., Tristani, F.E., Dunkman, W.B., Jacobs, W., Francis, O.S., Flohr, K.H., et al. 1986. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. New Engl. J. Med. 314:1547-1552.
6. Cohn, J.N. 1992. Mechanisms of action and efficacy of nitrates in heart failure. Am. J. Cardiol. 70: 88B-92B.
7. Hou, J., Kato, H., Cohen, R.A., Chobanian, A.V. and Brecher, P. 1995. Angiotensin II-induced cardiac fibrosis in the rat is increased by chronic inhibition of nitric oxide synthase. J. Clin. Invest. 96: 2469-2477.
8. Elkayam, U., Kulick, D., McIntosh, N., Roth, A., Hsueh, W. and Rahimtoola, S.H. 1987. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation 76: 577-584.
9. Elkayam, U. 1991. Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention. Ann. Intern. Med. 114: 667-677.
10. Ishikawa, K., Yamamoto, T., Kanamasa, K., Hayashi, T., Takenaka, T., Kimura, A., Miyataka, M., Yabushita, H. and Kitayama, K. 2000. Intermittent nitrate therapy for prior myocardial infaraction does not induce rebound angina nor reduce cardiac events. Intern. Med. 39:1020-1026.
11. Jugdutt, B.I. and Warnica, J.W. 1988. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location. Circulation 78: 906-919.
12. Jugdutt, B.I. and Khan, M.I. 1994. Effect of prolonged nitrate therapy on left ventricular remodeling after canine acute myocardial infarction. Circulation 89: 2297-2307.
13. Kai, H., Muraishi, A., Sugiu, Y., Nishi, H., Seki, Y., Kuwahara, F., Kimura, A., Kato, H. and Imaizumi, T. 1998. Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ. Res. 83: 594-601.
14. Kirn, N.N., Villegas, S., Summerour, S.R. and Villarreal, F.J. 1999. Regulation of cardiac fibroblast extracellular matrix production by bradykinin and nitric oxide. J. Mol. Cell. Cardiol. 31: 457-466.
15. Kobayashi, N., Higashi, T., Hara, K., Shirataki, H. and Matsuoka, H. 1999. Effects of imidapril on NOS expression and myocardial remodelling in failing heart of Dahl salt-sensitive hypertensive rats. Cardiovasc. Res. 44: 518-526.
16. Kolpakov, V., Gordon, D. and Kulik, T.J. 1995. Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells. Circ. Res. 6: 305-309.
17. Kurisu, S., Ozono, R., Oshima, T., Kambe, M., Ishida, T., Sugino, H., Matsuura, H., Chayama, K., Teranishi, Y., Iba, O., Amano, K. and Matsubara, H. 2003. Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension 41: 99-107.
18. Kuwahara, F., Kai, H., Tokuda, K., Kai, M., Takeshita, A., Egashira, K. and Imaizumi, T. 2002. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106: 130-135.
19. Leier, C.V. Nitrate tolerance. 1985. Am. Heart J. 110: 224-232.
20. Massie, B., Chatterjee, K., Werner, J., Greenberg, B., Hart, R. and Parmley, W.W. 1977. Hemodynamic advantage of combined administration of hydralazine orally and nitrates non-parenterally in the vasodilator therapy of chronic heart failure. Am. J. Cardiol 40:794-801.
21. Matsuoka, H., Nakata, M., Kohno, K., Koga, Y., Nomura, G., Toshima, H. and Imaizumi, T. 1996. Chronic L-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. Hypertension 27: 14-18.
22. McDonald, K.M., Francis, G.S., Matthews, J., Hunter, D. and Cohn, J.N. 1993. Long-term oral nitrate therapy prevents chronic ventricular remodeling in the dog. J. Am. Coll. Cardial. 21: 514-522.
23. Morkin, E. and Ashford, T.P. 1968. Myocardial DNA synthesis in experimental cardiac hypertrophy. Am. J. Physiol. 215: 1409-1413.
24. Muller, S., Laber, U., Mullenheim, J., Meyer, W. and Kojda, G. 2003. Preserved endothelial function after long-term eccentric isosorbide mononitrate despite moderate nitrate tolerance. J. Am. Coll. Cardiol. 41: 1994-2000.
25. Parmley, W.W. 1985. Role of isosorbide dinitrate in management of chronic congestive heart failure. Am. Heart. J. 110: 264-268.
26. Palmer, R.M., Ferrige, A.G. and Moncada, S. 1987. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (Lond.) 327: 524-526.
27. Rossi, M.A., Ramos, S.O. and Prado, C.M. 2003. Chronic inhibition of nitric oxide synthase induces hypertension and cardiomyocyte mitochondrial and myocardial collagen remodelling in the absence of hypertrophy. J. Hypertens. 21: 993-1001.
28. Rudolph, W., Dirschinger, J., Reiniger, G., Beyerle, A. and Hall, D. 1988. When does nitrate tolerance develop? What dosages and which intervals are necessary to ensure maintained effectiveness? Ear. Heart J. 9: 63-72.
29. Schwarz, F., Flameng, W., Schaper, J., Langebartels, F., Sesto, M., Hehrlein, F. and Schlepper, M. 1978. Myocardial structure and function in patients with aortic valve disease and their relation to postoperative results. Am. J. Cardiol. 41: 661-669.
30. Trachtman, H., Futterweit, S. and Singhal, P. 1995. Nitric oxide modulates the synthesis of extracellular matrix proteins in cultured rat mesangial cells. Biochem. Biopkys. Res. Commun. 207: 120-125.
31. Weber, K.T. and Brilla, C.G. 1991. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83: 1849-1865.
32. Weber, K.T., Brilla, C.G., Campbell, S.E., Zhou, G., Matsubara, L. and Guarda, E. 1992. Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Press. 1: 75-85.
33. Wollert, K.C., Fiedler, B., Gambaryan, S., Smolenski, A., Heineke, J., Butt, E., Trautwein, C., Lohmann, S.M. and Drexler, H. 2002. Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes. Hypertension 39: 87-92.
34. Yang, G., Meguro, T., Hong, C., Asai, K., Takagi, G., Karoor, V.L., Sadoshima, J., Vatner, D.E., Bishop, S.P. and Vatner, S.F. 2001. Cyclosporine reduces left ventricular mass with chronic aortic banding in mice, which could be due to apoptosis and fibrosis. J. Mol. Cell. Cardiol. 33:1505-1514.